» Articles » PMID: 24597602

Modulation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV1) and Norepinephrine Transporters (NET) Protect Against Oxidative Stress, Cellular Injury, and Vascular Dementia

Overview
Date 2014 Mar 7
PMID 24597602
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic cerebral hypoperfusion (CCH) is a risk factor for the development of vascular dementia (VaD). CCH participates in a negative role in cognitive impairments. Transient receptor potential vanilloid subtype 1 (TRPV1) participates in cognition, ischemic damage and neuroprotection. Selective norepinephrine transporter (NET) inhibitors have a role in cognitive dysfunction and oxidative stress. The role of TRPV1 and NET in CCH induced VaD is still unknown. The present study has been structured to investigate the role of vanillin; a selective agonist of TRPV1 as well as atomoxetine; a selective NET inhibitor in CCH induced VaD in mice. Permanent bilateral common carotid arteries ligation or two vessel occlusion (2VO) technique was used to induce a stage of chronic cerebral hypoperfusion in mice. 2VO animals have shown significant impairment of locomotion (Actophotometer), motor coordination (Rota rod), learning and memory (Morris water maze). 2VO animals have shown significant reduction in brain catalase, glutathione, and superoxide dismutase, with significant increase in brain infarct size (TTC staining), malondialdehyde and acetyl cholinesterase-AChE activity. Whereas, administration of vanillin as well as atomoxetine has significantly attenuated 2VO induced impaired locomotion, motor coordination, learning and memory, brain damage, brain oxidative stress and higher AChE activity. It may be concluded that 2VO induced CCH has elicited VaD, which was attenuated by vanillin and atomoxetine. Thus, modulators of vanilloid receptors and norepinephrine transporter may be explored further for their benefits in CCH induced VaD.

Citing Articles

Brivaracitam Ameliorates Increased Inflammation, Oxidative Stress, and Acetylcholinesterase Activity in Ischemic Mice.

Deval C, Sharma P, Sharma B, Singh B Clin Psychopharmacol Neurosci. 2025; 23(1):120-132.

PMID: 39820118 PMC: 11747741. DOI: 10.9758/cpn.24.1216.


Selective inhibition of T-type calcium channel preserves ischemic pre-conditioning mediated neuroprotection during cerebral ischemia reperfusion injury in diabetic mice.

Sharma P, Sharma B, Kharkwal H, Ghildiyal S, Patil V Metab Brain Dis. 2024; 40(1):33.

PMID: 39570531 DOI: 10.1007/s11011-024-01470-0.


Salubrious effects of ulinastatin and quercetin alone or in combination in endothelial dysfunction and vascular dementia.

Sharma P, Gaur N, Jayant S, Sharma B, Singh B, Kharkwal H Pharmacol Rep. 2022; 74(3):481-492.

PMID: 35396697 DOI: 10.1007/s43440-022-00364-1.


Block of Voltage-Gated Sodium Channels by Atomoxetine in a State- and Use-dependent Manner.

Fohr K, Nastos A, Fauler M, Zimmer T, Jungwirth B, Messerer D Front Pharmacol. 2021; 12:622489.

PMID: 33732157 PMC: 7959846. DOI: 10.3389/fphar.2021.622489.


Combined network pharmacology and virtual reverse pharmacology approaches for identification of potential targets to treat vascular dementia.

Lagunin A, Ivanov S, Gloriozova T, Pogodin P, Filimonov D, Kumar S Sci Rep. 2020; 10(1):257.

PMID: 31937840 PMC: 6959222. DOI: 10.1038/s41598-019-57199-9.